drugset / Trial / NCT04551924

A Trial of HR18034 in Inguinal Hernia Repair

NCT04551924

Phase 1 Unknown 64 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

Phase I, randomized, double-blind, comparator-controlled study to assess the safety, PK, and efficacy of single postsurgical application of HR18034 compared with Naropin®

Timeline

Start
2020-10-01
Primary completion
2021-05-30
Completion
2021-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HR18034 Unknown
Comparator Ropivacaine Other / unclassified 150 mg Other

Indications

No indication recorded.